PMC6180863_01
Contrast-enhanced MRI of the mediastinum: coronal slice. Block arrow: recurrent tumour, pre-treatment (November 2011). Broken arrow: level of previous surgical resection and end-to-end anastomosis.
bjrcr.20150201.g001.jpg
PMC6180863_01_bjrcr.20150201.g001.jpg
fig1
Investigations, including CT/MRI of the thorax, demonstrated a mass in the trachea (Figures 1 and 2).
Contrast-enhanced MRI of the mediastinum: axial slice. Block arrow: recurrent tumour, pre-treatment (November 2011).
bjrcr.20150201.g002.jpg
PMC6180863_01_bjrcr.20150201.g002.jpg
fig2
Investigations, including CT/MRI of the thorax, demonstrated a mass in the trachea (Figures 1 and 2).
Isodose demonstrating coverage of at least 95%, 5 mm from the clinical target volume.
bjrcr.20150201.g003.jpg
PMC6180863_01_bjrcr.20150201.g003.jpg
fig3
The planning target volume (PTV) was obtained by expanding the CTV by 5 mm in all directions (Figure 3).
Contrast-enhanced MRI of the mediastinum: axial slice. Block arrow: reduction in tumour size, 1 year post-treatment (November 2012).
bjrcr.20150201.g004.jpg
PMC6180863_01_bjrcr.20150201.g004.jpg
fig4
These serial MRIs showed a gradual disease response with reduction in the size of the ACC (Figures 4 and 5).
Contrast-enhanced MRI of the mediastinum: axial slice. Block arrow: further reduction in tumour size, 3 years post-treatment (November 2014).
bjrcr.20150201.g005.jpg
PMC6180863_01_bjrcr.20150201.g005.jpg
fig5
These serial MRIs showed a gradual disease response with reduction in the size of the ACC (Figures 4 and 5).